Efficacy and cosmetic properties of drug forms of hydrocortisone 17-butyrate for patients with allergic contact dermatitis: a prospective observational program

Cover Page

Cite item


Objective. To assess the duration of the therapy needed for complete eradication of clinical manifestations of allergic contact dermatitis (ACD) and evaluate how patients perceive cosmetic properties of Locoid, and to assess etiological factors of ACD based on the medical history. Materials and methods. The authors performed an open multicenter prospective observational program of observations of ACD patients receiving treatment with Locoid (in the form of Lipocream or Crelo). As many as 149 patients were involved. The patients received treatment with Locoid according to the routine practice until complete eradication of the lesions but for not more than 30 days. Prior to the onset of treatment, the etiological factor that caused ACD was evaluated. Upon the completion of the therapy, patients completed questionnaire forms to assess the cosmetic properties of the drug. Results. The authors demonstrated high clinical efficacy of the drug: ACD symptoms were eradicated in 96.64% of the patients; the median treatment duration amounted to 7 days. Cosmetic properties of the drug and general satisfaction with treatment were high regardless of the drug form (Lipocream or Crelo). In the sample under observation, the use of different cosmetic products was the most frequent reason of ACD. High safety of Locoid was demonstrated: adverse events were observed in one patient only. Conclusion. The duration of the therapy needed for complete eradication of clinical manifestations of allergic contact dermatitis is 7 days (median: quartiles of 5-9 days). The perception of cosmetic properties of both Locoid drug forms (Lipocream or Crelo) is positive; general satisfaction with treatment is high and does not depend on the drug form.

About the authors

A. A. Kubanov

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: noemail@neicon.ru
Russian Federation

A. E. Karamova

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Email: karamova@cnikvi.ru
Russian Federation


  1. Российское общество дерматовенерологов и косметологов. Федеральные клинические рекомендации по ведению больных контактным дерматитом. М, 2013. Доступно по адресу: http://www.cnikvi.ru/docs/clinic_ recs/bolezni-kozhi-i-pridatkov-kozhi/kontakt-nyy_dermatit.doc
  2. Bourke J., Coulson I., English J. British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of contact dermatitis: an update. Br J Dermatol 2009; 160 (5): 946-54.
  3. Becker D. Allergic contact dermatitis. J Dtsch Dermatol Ges 2013; 11 (7): 607-19.
  4. Krob H.A., Fleischer A.B. Jr, D’Agostino R. Jr, Haverstock C.L., Feldman S. Prevalence and relevance of contact dermatitis allergens: a meta-analysis of 15 years of published T.R.U.E. test data. J Am Acad Dermatol 2004; 51 (3): 349-353.
  5. Stepanova E.V. Allergicheskij kontaktnyj dermatit: osnovnye podhody k diagnostike, lecheniju i profilaktike. Lechashhij vrach 2009; 10: 15-19.
  6. Jacob S.E., Steele T. Corticosteroid classes: a quick reference guide including patch test substances and cross-reactivity. J Am Acad Dermatol 2006; 54 (4): 723-7.
  7. Miller J.A., Munro D.D. Topical corticosteroids: clinical pharmacology and therapeutic use. Drugs 1980; 19: 119-134.
  8. Fowler J.F. Jr, Fransway A.F., Jackson J.M., Rohowsky N. Hydrocortisone butyrate 0.1% cream in the treatment of chronic dermatitis. Cutis. 2005; 75 (2): 125-31.
  9. Barbinov V.V., Belousova I.Je., Sokolova M.V., Hajrutdinov V.R. Racional'noe ispol'zovanie sovremennyh topicheskih gljukokortikosteroidnyh preparatov v praktike dermatovenerologa. Jeffektivnaja farmakoterapija. Dermatovenerologija i dermatokosmetologija 2014; 2: 38-40.
  10. Aslam I., Sandoval L.F., Feldman S.R. What's new in the topical treatment of allergic skin diseases. Curr Opin Allergy Clin Immunol 2014 Oct; 14 (5): 436-50.

Copyright (c) 2015 Kubanov A.A., Karamova A.E.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies